Biotest AG
Biotest AG: Discussions regarding business combination
Biotest AG / Key word(s): Merger Ad-hoc RELEASE Dreieich, 29 March 2017. Biotest Aktiengesellschaft and Creat Group Corporation, a leading Chinese investment group, are currently in discussions regarding a potential business combination. Creat is a long-term strategic investor. Creat Group Corporation indicated certain key parameters of a potential combination to be implemented through a public tender offer for all common and preference shares of Biotest Aktiengesellschaft. The envisaged consideration is EUR 28.50 per ordinary share and EUR 19.00 per preference share of Biotest Aktiengesellschaft. Any potential transaction is still subject to final negotiations of a business combination agreement and an agreement with Biotest Aktiengesellschaft’s majority shareholder, OGEL GmbH, as well as finalization of due diligence and the required financing measures. There can be no assurance that a final agreement between the two parties will be reached or that any such offer will be made. Biotest Aktiengesellschaft Biotest AG Disclaimer IR contact Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Contact: Dr. Michael Ramroth Chief Financial Officer Biotest AG Landsteinerstr. 3 63303 Dreieich Tel. +40 6103 801 338 Fax: +49 6103 801 347 Michael.ramroth@biotest.com
29-March-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 – 8 01-0 |
Fax: | 0 61 03 – 8 01-150 |
E-mail: | investor_relations@biotest.de |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of Announcement | DGAP News Service |